Comparative Pharmacology
Head-to-head clinical analysis: CORTALONE versus PSORCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTALONE versus PSORCON.
CORTALONE vs PSORCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortisone is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to suppress inflammation and immune response, and regulate metabolism.
Psorcon (diflorasone diacetate) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. It inhibits the release of arachidonic acid, thereby decreasing the formation of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
10-40 mg orally once daily in the morning; for acute exacerbations, up to 60 mg/day divided into 2-4 doses.
Apply a thin layer to affected skin twice daily. For scalp conditions, use lotion or shampoo as directed.
None Documented
None Documented
Terminal elimination half-life is 3-5 hours in patients with normal renal function; prolonged to 12-24 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 2 hours (range 1.5–3 hours) after topical application; clinical significance: short half-life allows twice-daily dosing.
Primarily renal (60-70% as unchanged drug), with 10-20% biliary/fecal.
Primarily renal (about 70% as unchanged drug and metabolites); biliary/fecal elimination of approximately 30%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid